RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

Takeda is walking away from the last target in a collaboration with Wave Life Scien | Takeda has brandished a termination ...

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

Wave Life Sciences (WVE) said Takeda (TAK) has elected not to exercise its option to further develop its Huntington’s disease ...

Takeda Pharmaceutical offers a strong cash position and an above-average dividend yield. Find out why I'm bullish on TAK ...

HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral ...

There is no simple solution to tackling health inequity, but we’re confident that infusing health equity principles across ...

The vaccine began being administered through the public health sysem in February this year. It was prioritized for children ...

The T. Rowe Price Japan Fund (Trades, Portfolio), known for its strategic investments in a diverse array of Japanese industries, has recently disclosed its N-PORT filing for the third quarter of 2024.

There may be no greater demonstration of vaccines’ power to deliver health equity than their success with smallpox. “The ...

Leadership succession strategy, which includes a new CFO appointment and creation of a new CCO role is expected to bolster ...

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...